Revenue: As of FY2025, the actual value is USD 0.EPS: As of FY2025, the actual value is USD -5.48.EBIT: As of FY2025, the actual value is USD -20.5 M.<h4>Financial Performance Overview</h4><ul><li>Net Loss: Reviva Pharmaceuticals Holdings, Inc. reported a net loss of - $19.9 million for the year ended December 31, 2025, an improvement from a net loss of - $29.9 million for the year ended December 31, 2024.</li><li>Accumulated Deficit: As of December 31, 2025, the company had an accumulated deficit of - $184.1 million.</li><li>Working Capital Surplus: The working capital surplus was $7.8 million as of December 31, 2025, a significant increase from $81,861 as of December 31, 2024, representing a 9462.5% increase.</li><li>Total Assets: Total assets increased by 2.7% to $15,923,198 as of December 31, 2025, from $15,503,088 as of December 31, 2024.</li><li>Total Stockholders’ Equity: Total stockholders’ equity saw a substantial increase of 964.2% to $8,647,645 as of December 31, 2025, from $812,572 as of December 31, 2024.</li></ul><h4>Operating Expenses</h4><ul><li>Research and Development (R&amp;D) Expenses: These decreased by - $11.2 million, or 48.9%, from $22,907,368 in 2024 to $11,708,906 in 2025.<ul><li>Internal salaries, wages, and other payroll-related costs for R&amp;D employees were approximately $2.3 million in both 2025 and 2024.</li><li>Internal stock-based compensation expenses for R&amp;D employees were approximately $0.8 million in 2025, down from $1.0 million in 2024.</li><li>External R&amp;D expenses were approximately $8.6 million in 2025, down from $19.6 million in 2024.</li><li>Clinical research costs were approximately $6.9 million in 2025, compared to $15.5 million in 2024.</li><li>Non-clinical safety related costs were approximately $0.8 million in 2025, down from $1.3 million in 2024.</li><li>Non-clinical manufacturing related costs were approximately $0.6 million in 2025, down from $2.4 million in 2024.</li><li>Non-clinical consulting and other related costs were approximately $0.3 million in 2025, down from $0.4 million in 2024.</li></ul></li><li>General and Administrative (G&amp;A) Expenses: These increased by $0.6 million, or 7.6%, from $7,891,521 in 2024 to $8,491,125 in 2025.<ul><li>Stock-based compensation expense was approximately $1.4 million in 2025, up from $0.7 million in 2024.</li><li>Consultant and professional expenses were approximately $3.0 million in 2025, down from $3.4 million in 2024.</li><li>Legal expenses were approximately $1.7 million in 2025, up from $1.2 million in 2024.</li><li>Employee-related expenses were approximately $1.7 million in 2025, down from $1.8 million in 2024.</li><li>Directors and Officers insurance expenses were approximately $0.4 million in 2025, down from $0.5 million in 2024.</li><li>Other general and administrative expenses remained consistent at approximately $0.3 million in both periods.</li></ul></li></ul><h4>Other Income and Expenses</h4><ul><li>Gain on Remeasurement of Warrant Liabilities: A gain of $0.1 million was recognized in 2025, compared to $0.7 million in 2024, primarily due to a decrease in fair value and expiration of warrants.</li><li>Interest Expense: Decreased to - $13.4 thousand in 2025 from - $18.5 thousand in 2024, due to reduced interest rates on short-term debt.</li><li>Interest Income: Decreased to $0.3 million in 2025 from $0.4 million in 2024, primarily due to declining average cash balances and market interest rates.</li><li>Other Expense, net: Decreased to - $33 thousand in 2025 from - $0.2 million in 2024, mainly due to a lower foreign currency transaction loss.</li></ul><h4>Cash Flow Data</h4><ul><li>Net Cash Used in Operating Activities: Approximately - $24.6 million in 2025, an improvement from - $33.5 million in 2024.</li><li>Net Cash Provided by Financing Activities: Approximately $25.6 million in 2025, up from $23.7 million in 2024, including funds from ATM offerings, common stock, warrants, and warrant exercises.</li><li>Net Increase (Decrease) in Cash and Cash Equivalents: An increase of $962,461 in 2025, compared to a decrease of - $9,891,125 in 2024.</li></ul><h4>Outlook</h4>Reviva Pharmaceuticals Holdings, Inc. had cash and cash equivalents of $14.4 million as of December 31, 2025, but anticipates that existing cash will be insufficient to meet operating and capital requirements for at least 12 months from the filing date. The company plans to initiate trial-related activities for the RECOVER-2 Phase 3 study for brilaroxazine in Q2-2026, with patient enrollment starting in Q3-2026 and study completion expected in Q4-2027.

Reviva Pharmaceuticals | 10-K: FY2025 Revenue: USD 0